Showing results (41-50 of 67) with videos related to
Sort By:
Pageof 7
JCO Precision Oncology|January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung CancerJustin F Gainor, Diane Tseng, Satoshi Yoda, et al.Cancer Discovery|March 2, 2023
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic CancerYoann Pradat, Julien Viot, Andrey A Yurchenko, et al.Cancer Discovery|June 28, 2023
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial CancerFrancesco Facchinetti, Antoine Hollebecque, Floriane Braye, et al.NPJ Precision Oncology|February 26, 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patientsDamien Vasseur, Ahmadreza Arbab, Fabiola Giudici, et al.The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni SyndromeLaura Mezquita, Maria Jové, Ernest Nadal, et al.JCO Precision Oncology|September 14, 2020
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung CancerLaura Mezquita, Aurélie Swalduz, Cécile Jovelet, et al.Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.Pageof 7